NEWS

At over $0.9 billion, Colombotai licensed another ADC drug from Mercadon.

Release time:

2022-08-10 13:21

July 26, 2022Korenbotai announced that he and Mercadon (MSD) reachedCooperation and Exclusive License Agreement, to develop a for the treatment of solid tumors.Antibody conjugate (ADC）Drugs.

AccordingContent of Agreement, Korenbotai wantsPaid exclusive licenseMerck develops, produces and commercializes this model worldwide.ADC drugs. The two companies will also collaborate on the early clinical development of the ADC drug.Merck will pay Korenbotai in accordance with the content of the agreement and the commercial development phase.A down payment of $35 million, various milestone payments up to $0.901 billion and the corresponding commission on net sales.. According to the Collen pipeline, the probability of this authorization isClaudin 18.2 ADC 新药 SKB315。

Prior to this collaboration, Korenbotai was launched this year.May announced a paid and exclusive license for Merck to develop, produce and commercialize targeted products outside China (including mainland China, Hong Kong, Macau and Taiwan).ADC drug SKB-264 of TROP2.The two parties will collaborate on specific early clinical development initiatives, including exploringSKB-264 monotherapy and combination with Coretta®(KEYTRUDA®, pembrolizumab) potential value for the treatment of advanced solid tumors. This transaction includes$47 million Down Payment, not more$1.363 billion Milestone Paymentand a commission on net sales after the product is marketed. This KorenBotaiReaching another blockbuster deal with Merck further proves Koren's research and development strength and is another milestone for Koren's new drug to go to sea.

The above-mentioned licensing cooperation cases reflect the intellectual property rights as an important intellectual asset of enterprises., It plays an important role in the core competitiveness of enterprises:Promote enterprise technological innovation, enhance core competitiveness, broaden market space, and bring new profit growth pointsWait.

 

Adc, Merck, cooperation, licensing, drug, development, enterprise, research and development, agreement.